




NONVIRAL EX VIVO **MODIFICATION OF CELL** THERAPY-RELEVANT **CELL TYPES**

Transfection is the process of introducing foreign material - generally nucleic acids (DNA or RNA) - into cells. Introduction of foreign nucleic acids using various chemical, biological, or physical methods can result in a change of the properties of the cell, allowing for the study of gene function and protein expression in the context of the cell, or transformation of the cell into a potential cell therapy product such as a CAR T cell.



Apply electrical pulse to sample

Assay cells for transfection efficiency and viability



OPTIMIZE YOUR ELECTROPORATION PROTOCOLS BY CONTROLLING KEY FACTORS THAT DIRECTLY AFFECT PERFORMANCE:



Voltage

З



Pulse number






Buffer conductance/ resistance


VOLTAGE IS THE MOST SIGNIFICANT FACTOR TO IMPACT FUNCTIONAL PERFORMANCE

Analysis of CART cell transfection with three leukapheresis-derived T cell donors, using Cas9/gRNA to knock out the endogenous T cell receptor (TCR) and knock in a double-stranded, linear DNA expressing a second-generation CAR construct. 5 x 107 cells/mL transfected on the Invitrogen™ Neon™ Transfection System (100 µL), or the CTS Xenon instrument, with a Gibco™ Xenon™ SingleShot chamber (1 mL) or a Gibco™ Xenon™ MultiShot cartridge (9 mL), or were left untransfected. Cells were assessed through flow cytometry four days after transfection for gene expression of CD19 on the CAR T cells. Cells were also assessed for viability with a cell counter utilizing Gibco™ Trypan Blue solution.




% Total Edited Cells (%KO + %KI)


Pulse width




Donor 3 TCRαβ+(%)



% Viability (Trypan Blue exclusion)





OTHER IMPORTANT ATTRIBUTES OF A CELL THERAPY ELECTROPORATION SYSTEM:


Scalable, flexible electroporation protocols

GMP manufactured consumables

Closed system processing



Equivalent performance at small and large scale



THE GIBCO CTS XENON ELECTROPORATION SYSTEM:

- High speed, large volume—transfect up to 2.5 x 10⁹ T cells in less than 25 minutes
- Proven performance and viability—up to 90% gene knockout and 80% viability
- Process flexibility—user-programmable system helps enable you to create and optimize electroporation protocols for various cell types and payloads from process development through commercial manufacturing
- Nonviral transfection—can be used to deliver DNA, RNA, and protein payloads
- Closed-system processing—MultiShot (MS) consumable enables sterile welding to PVC or C-Flex[™] tubing

Putting solutions into practice:

evolve your process from research to commercial scale

Prioritize process improvement without sacrificing time-to-market by utilizing closed, modular and automated systems

> Compatible digital and physical connections support utomation, use of pre-se protocols or custom er-programmed equences



dapt to evolving needs using modula integration of nev echnologies into old processes

Scalable endpoint analytics allow careful nonitoring with minimal touchpoints, reducing risk of contamination

Minimize potential

and protocols

Thermo Fisher is dedicated to providing solutions to help customers overcome hurdles from every angle of their cell therapy production processes. Visit thermofisher.com/CGT to learn more.

Find out more and request a demo at thermofisher.com/xenon

Intended use of the products mentioned in this document varies. For specific intended use statements, please refer to the Instructions for Use (IFU).

Caution: Not intended for direct administration into humans or animals.

Thermo Fisher SCIENTIFIC

